Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.